{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:10:20Z","timestamp":1790712620558,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI23\/00164"],"award-info":[{"award-number":["PI23\/00164"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI20\/00592"],"award-info":[{"award-number":["PI20\/00592"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00592"],"award-info":[{"award-number":["PI20\/00592"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00164"],"award-info":[{"award-number":["PI23\/00164"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejim.2026.107200","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:31:22Z","timestamp":1790220682000},"page":"107200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating angiogenic and inflammatory biomarkers profiling in patients with hereditary hemorrhagic telangiectasia"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-7062","authenticated-orcid":false,"given":"Bernat","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9204-9888","authenticated-orcid":false,"given":"Raquel","family":"Torres-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0271-1767","authenticated-orcid":false,"given":"Miriam","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia-Ainhoa","family":"Sanz-Astier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-4044","authenticated-orcid":false,"given":"Alfredo","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5366-6613","authenticated-orcid":false,"given":"Laura","family":"Ochoa-Callejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-4307","authenticated-orcid":false,"given":"Jes\u00fas","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-6751","authenticated-orcid":false,"given":"Francesc","family":"Vi\u00f1als","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-5887","authenticated-orcid":false,"given":"Gael","family":"Genet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-804X","authenticated-orcid":false,"given":"Antoni","family":"Riera-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejim.2026.107200_bib0001","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/bloodadvances.2023011961","article-title":"Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.ejim.2026.107200_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.medcli.2018.09.015","article-title":"Medical management of haemorrhagic hereditary telangiectasia in adult patients","volume":"152","author":"Riera-Mestre","year":"2019","journal-title":"Med Clin"},{"issue":"12","key":"10.1016\/j.ejim.2026.107200_bib0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0004","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-020-01422-8","article-title":"Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry","volume":"15","author":"S\u00e1nchez-Mart\u00ednez","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ejim.2026.107200_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2015.00001","article-title":"Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era","volume":"6","author":"McDonald","year":"2015","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0007","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/VB-21-0019","article-title":"Rethinking growth factors: the case of BMP9 during vessel maturation","volume":"4","author":"Medina-Jover","year":"2022","journal-title":"Vasc Biol"},{"issue":"2","key":"10.1016\/j.ejim.2026.107200_bib0008","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10456-021-09785-7","article-title":"Vascular endothelial cell specification in health and disease","volume":"24","author":"Marziano","year":"2021","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.ejim.2026.107200_bib0009","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176379","article-title":"Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances","volume":"134","author":"Al Tabosh","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2026.107200_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2023.05.020","article-title":"Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases","volume":"115","author":"Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"23","key":"10.1016\/j.ejim.2026.107200_bib0011","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.3390\/ijms21239247","article-title":"Endoglin: an 'Accessory' Receptor regulating blood cell development and inflammation","volume":"21","author":"Meurer","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.ejim.2026.107200_bib0012","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rce.2018.07.002","article-title":"Computerized registry of patients with hemorrhagic hereditary telangiectasia (RiHHTa Registry) in Spain: objectives, methods, and preliminary results","volume":"218","author":"Riera-Mestre","year":"2018","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ejim.2026.107200_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1146080","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"10","author":"Torres-Iglesias","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/jcm9010082","article-title":"Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: risk factors and endoscopic findings","volume":"9","author":"Mora-Luj\u00e1n","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ejim.2026.107200_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2026033112","article-title":"Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the comprehensive HHT outcomes registry of the US (CHORUS)","volume":"148","author":"Al-Samkari","year":"2026","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejim.2026.107200_bib0016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0028-1085093","article-title":"Hepatic vascular malformations in hereditary hemorrhagic telangiectasia","volume":"28","author":"Khalid","year":"2008","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.ejim.2026.107200_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228486","article-title":"Bevacizumab for treating hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia","volume":"15","author":"V\u00e1zquez","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejim.2026.107200_bib0018","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejim.2026.107200_bib0019","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.ejim.2026.107200_bib0020","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of cardiovascular disease: molecular basis and practical considerations","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107200_bib0021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejim.2021.09.003","article-title":"Translational medicine in hereditary hemorrhagic telangiectasia","volume":"95","author":"Riera-Mestre","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2026.107200_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fgene.2015.00115","article-title":"Research on potential biomarkers in hereditary hemorrhagic telangiectasia","volume":"6","author":"Botella","year":"2015","journal-title":"Front Genet"},{"key":"10.1016\/j.ejim.2026.107200_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2021.03.039","article-title":"Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia","volume":"88","author":"Iriarte","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0026","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/lary.27548","article-title":"Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis","volume":"129","author":"Steineger","year":"2019","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.ejim.2026.107200_bib0027","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13023-021-02009-7","article-title":"Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations","volume":"16","author":"Wetzel-Strong","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.ejim.2026.107200_bib0028","article-title":"Evolution of angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia during treatment with bevacizumab: study protocol","volume":"225","author":"Villanueva","year":"2025","journal-title":"Rev Clin Esp"},{"issue":"10","key":"10.1016\/j.ejim.2026.107200_bib0029","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ajh.70011","article-title":"Standardization of terminology, definitions, and outcome criteria for bleeding in hereditary hemorrhagic telangiectasia: international consensus report","volume":"100","author":"Al-Samkari","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.ejim.2026.107200_bib0030","first-page":"803","article-title":"Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"110","author":"McShane","year":"2018","journal-title":"Nat Clin Pr Urol"},{"issue":"35","key":"10.1016\/j.ejim.2026.107200_bib0031","doi-asserted-by":"crossref","first-page":"57197","DOI":"10.18632\/oncotarget.11084","article-title":"The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance","volume":"7","author":"Alidzanovic","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.ejim.2026.107200_bib0032","doi-asserted-by":"crossref","first-page":"9886","DOI":"10.1158\/0008-5472.CAN-10-1419","article-title":"Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model","volume":"70","author":"Stefanini","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejim.2026.107200_bib0033","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006627","article-title":"Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2","volume":"2","author":"Lawler","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"10.1016\/j.ejim.2026.107200_bib0034","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-07-4081","article-title":"Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels","volume":"14","author":"Brostjan","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejim.2026.107200_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-023-09900-w","article-title":"Role of endothelial PDGFB in arterio-venous malformations pathogenesis","volume":"27","author":"Lin","year":"2024","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.ejim.2026.107200_bib0036","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"47","key":"10.1016\/j.ejim.2026.107200_bib0037","doi-asserted-by":"crossref","first-page":"77902","DOI":"10.18632\/oncotarget.12843","article-title":"PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejim.2026.107200_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mvr.2016.01.005","article-title":"Anti-vascular endothelial growth factor treatment induces blood flow recovery through vascular remodeling in high-fat diet induced diabetic mice","volume":"105","author":"Xiao","year":"2016","journal-title":"Microvasc Res"},{"issue":"7\u20138","key":"10.1016\/j.ejim.2026.107200_bib0039","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cca.2009.12.023","article-title":"Reduced plasma levels of ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT)","volume":"411","author":"Ojeda-Fernandez","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"17","key":"10.1016\/j.ejim.2026.107200_bib0040","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.3390\/ijms23179660","article-title":"The VEGF inhibitor soluble fms-like Tyrosine kinase 1 does not promote AKI-to-CKD transition","volume":"23","author":"van Aanhold","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2026.107200_bib0041","first-page":"E7","article-title":"Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors","volume":"1207","author":"Pavlakovic","year":"2010","journal-title":"Ann N Acad Sci"},{"issue":"23","key":"10.1016\/j.ejim.2026.107200_bib0042","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/CIRCULATIONAHA.117.033062","article-title":"Decreased expression of vascular endothelial growth factor receptor 1 contributes to the pathogenesis of hereditary hemorrhagic telangiectasia type 2","volume":"138","author":"Thalgott","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejim.2026.107200_bib0043","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/CIRCRESAHA.116.310477","article-title":"VEGFR3 Modulates vascular permeability by controlling VEGF\/VEGFR2 signaling","volume":"120","author":"Heinolainen","year":"2017","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.ejim.2026.107200_bib0044","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.3390\/jcm9113571","article-title":"Potential second-hits in hereditary hemorrhagic telangiectasia","volume":"9","author":"Bernabeu","year":"2020","journal-title":"J Clin Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:31:34Z","timestamp":1790710294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526005054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0953620526005054"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107200","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating angiogenic and inflammatory biomarkers profiling in patients with hereditary hemorrhagic telangiectasia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107200"}}